# The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

> **NCT05422690** · PHASE2 · RECRUITING · sponsor: **Inova Health Care Services** · enrollment: 16 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** Induction Chemotherapy Triplet Therapy
- **RADIATION:** Concurrent Y-90 treatment
- **DRUG:** Consolidation Doublet Therapy:

## Key facts

- **NCT ID:** NCT05422690
- **Lead sponsor:** Inova Health Care Services
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-12
- **Primary completion:** 2026-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05422690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05422690, "The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05422690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*